Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6, indicating a small update to the page's version history.SummaryDifference0.0%

- Check19 days agoChange DetectedEligibility criteria text was refined by updating the ANC and bilirubin thresholds (removing and rewording prior criteria). A MedlinePlus Genetics reference was added under related topics to provide melanoma-related background information.SummaryDifference0.5%

- Check26 days agoChange DetectedMelanoma, the related topics header, and MedlinePlus Genetics were removed from the page's related topics section, reducing the topic labels shown with the study.SummaryDifference0.1%

- Check33 days agoChange DetectedA new revision marker 'Revision: v3.6.5' was added. Several related topics items were removed, including 'Melanoma', 'related topics:', 'MedlinePlus Genetics', and the older revision 'Revision: v3.6.4'.SummaryDifference0.2%

- Check40 days agoChange DetectedAdded related topics to the page: Melanoma and MedlinePlus Genetics, enhancing topic connections and navigation.SummaryDifference0.1%

- Check47 days agoChange DetectedFooter shows a revision update from v3.6.3 to v3.6.4. This reflects a small maintenance update to the page without changing study content or functionality.SummaryDifference0.0%

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.